Naloxone: Policies and Access
Policies have helped make naloxone more available, thus contributing to the reduction of opioid-related deaths in the U.S.
Opioid use was compared between a six-month control period and three months following education for prescribers on opioid administration routes, focusing on awareness of the subcutaneous routes.
Lucemyra, a selective alpha 2-adrenergic receptor agonist, works by reducing the release of norepinephrine and decreasing sympathetic tone.
Researchers examined the extent to which pharmaceutical industry marketing of opioid products to physicians during 2014 correlated with opioid prescribing in 2015.